Literature DB >> 9372339

High-dose etoposide treatment for CNS involvement in a patient with primary non-Hodgkin's lymphoma of the breast.

H Kohara1, H Ueoka, M Tabata, K Shinagawa, K Hayashi, M Harada.   

Abstract

A 46-year-old man was referred to us for treatment of non-Hodgkin's lymphoma (NHL; diffuse large immunoblastic B cell type), which had initially developed in the breast. He was treated with five courses of chemotherapy with CHOP (cyclophosphamide, adriamycin, vincristine, and prednisolone) and achieved a complete response. One year later, he noticed a gait disturbance. Magnetic resonance imaging (MRI) of the brain showed multiple nodules. A few abnormal cells were found in the cerebrospinal fluid (CSF). He was treated with high-dose etoposide (1,350 mg/ m2/course). After two courses, both the multiple nodular lesions in the brain and the abnormal cells in the CSF were resolved. High-dose etoposide is effective for CNS involvement by NHL.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9372339     DOI: 10.2169/internalmedicine.36.738

Source DB:  PubMed          Journal:  Intern Med        ISSN: 0918-2918            Impact factor:   1.271


  2 in total

1.  Upfront autologous stem-cell transplantation with melphalan, cyclophosphamide, etoposide, and dexamethasone (LEED) in patients with newly diagnosed primary central nervous system lymphoma.

Authors:  Kotaro Miyao; Reona Sakemura; Kanae Imai; Toshiyasu Sakai; Natsuko Tsushita; Tomonori Kato; Keiko Niimi; Yoshitaka Ono; Masashi Sawa
Journal:  Int J Hematol       Date:  2014-06-20       Impact factor: 2.490

2.  Diffuse Large B-Cell Lymphoma with Involvement of the Breast and Testis in a Male Patient.

Authors:  Eunji Choi; Jae-Cheol Jo; Dok Hyun Yoon; Shin Kim; Kyoungmin Lee; Jooryung Huh; Chan-Sik Park; Sang Wook Lee; Cheolwon Suh
Journal:  Cancer Res Treat       Date:  2014-09-11       Impact factor: 4.679

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.